Amgen, Inc. (NASDAQ:AMGN)
A biotechnology company which discovers, develops, manufactures and markets human therapeutics based on advances in cellular and molecular biology.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
MORTOMER
(< 20)
Submitted: 6/16/2007 11:34:37 AM :
Start Price:
$57.59
AMGN Score:
+29.24
Biotechnology is an upcoming resource the world is starting to use more and more. This one looks pretty solid to me.
Recs
ThatDayisNow
(< 20)
Submitted: 6/15/2007 1:07:44 AM :
Start Price:
$57.43
AMGN Score:
+29.42
Too solid of a company. Got beaten down by emotion and other sectors are too hot right now and too predictable to make money in. Once the market turns down this stock will slowly start it's climb.
Recs
TMFOpie
(98.09)
Submitted: 6/12/2007 7:11:33 PM :
Start Price:
$56.19
AMGN Score:
+30.09
Beaten down stock on concens over drug line and sustainability. Market leader selling at 13x earnings but no one wants to own this puppy. A great time own it.
Recs
rontdav
(82.63)
Submitted: 6/11/2007 10:35:11 PM :
Start Price:
$56.10
AMGN Score:
+30.39
always moving ahead in their field. my family has gotten rich off this stock since 1995. I believe they will have some home runs in the next couple of years.
Recs
jblakie
(86.29)
Submitted: 6/11/2007 12:50:37 PM :
Start Price:
$56.41
AMGN Score:
-30.28
The current litigation looks serious for the short term
Recs
The42ndDude
(86.40)
Submitted: 5/31/2007 1:35:29 PM :
Start Price:
$55.24
AMGN Score:
+33.87
Anemia thing's overblown. Now cheapest biotech by far. Only two issues: (1) Can they sell their drugs by themselves? If so, they save a lot by cutting the middleman. (2) Will Dems encourage biotech generics? Well big pharm survived and grew, so maybe this is overblown too. Anyway, not much down side.
Recs
AlexG06
(< 20)
Submitted: 5/29/2007 8:11:30 PM :
Start Price:
$53.13
AMGN Score:
+36.70
way oversold
Recs
KenyaJersey
(23.07)
Submitted: 5/27/2007 4:16:26 AM :
Start Price:
$53.62
AMGN Score:
+36.85
Finding a bottom after a storm of bad news. Strong pipeline and heavy R&D spending will begin to bear fruit and see this company rise beyond the short-term hiccup.
Recs
boca7rel
(73.57)
Submitted: 5/26/2007 3:11:37 PM :
Start Price:
$53.62
AMGN Score:
+36.85
low debt/equity ratio. P/E is less than 80% of industry P/E. stock pays dividends.
Recs
arrosen
(< 20)
Submitted: 5/23/2007 5:47:51 PM :
Start Price:
$53.95
AMGN Score:
+36.44
It is at a good price now. Hold it for a bit and it will shoot up.
Recs
waterflea
(93.09)
Submitted: 5/21/2007 5:54:13 PM :
Start Price:
$53.17
AMGN Score:
+38.40
A bargain price on a great company, because too many people want to make money today and not over the course of the next five years.
Recs
stone9
(97.26)
Submitted: 5/20/2007 10:35:37 PM :
Start Price:
$53.92
AMGN Score:
+36.54
The stock is just too cheap...
Recs
MadM0ney
(95.46)
Submitted: 5/18/2007 12:16:42 PM :
Start Price:
$52.94
AMGN Score:
+38.60
For short term the bad news is out its hit rock bottom. It may still be bumpy until the end of the year but look for the long term growth.
Recs
augiisis3
(50.64)
Submitted: 5/18/2007 12:05:29 PM :
Start Price:
$52.93
AMGN Score:
+38.58
new drugs coming online
Recs
mixepix
(33.05)
Submitted: 5/16/2007 8:46:58 PM :
Start Price:
$53.04
AMGN Score:
-37.92
Its two leading, profit making drugs under contiual scrutiny by the FDA and others, as well as nothing reaching near-term approval in the pipeline.
Recs
henncoop
(96.77)
Submitted: 5/16/2007 1:18:55 PM :
Start Price:
$53.29
AMGN Score:
+36.98
beaten down sector ; great value here with better days ahead
Recs
Sugarcreek
(52.03)
Submitted: 5/15/2007 10:16:39 PM :
Start Price:
$53.06
AMGN Score:
+37.52
A winner for years
Recs
SESAMEnow
(89.09)
Submitted: 5/15/2007 5:41:08 PM :
Start Price:
$53.06
AMGN Score:
+37.52
Earnings growth is 15%, P/E is a very reasonable 14 for this growth rate, recently marked has dropped share price so future looks good at this price....
Recs
luchon
(< 20)
Submitted: 5/15/2007 11:54:51 AM :
Start Price:
$52.24
AMGN Score:
+39.94
great biotech company that has slid on a patch of poor PR
Recs
TimberMist
(42.37)
Submitted: 5/11/2007 12:12:50 PM :
Start Price:
$54.51
AMGN Score:
+33.73
oversold on overreaction to what is nothing more than a labeling recommendation...
great buying op here....
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 161 - 180 of 333 : « Previous 4 5 6 7 8 9 10 11 12 13 Next »